Low‐dose nivolumab for extranodal natural killer/T‐cell lymphoma, nasal type

Satish Maharaj, Simone Chang · 2024

Read Low‐dose nivolumab for extranodal natural killer/T‐cell lymphoma, nasal type by Satish Maharaj, Simone Chang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647695.txt.

Description

Satish Maharaj and Simone Chang published a case report in 2024 on a rare lymphoma and low-dose immune therapy. The cancer strikes natural killer and T cells, often in the nose, and carries poor odds. Checkpoint drugs that free the immune system have shown promise when the disease returns.

Their patient was a 59-year-old man whose left nasal airway was nearly blocked by a tumor. Scans showed a mass in the left nasal cavity, and surgery both debulked it and took tissue for testing. Stains and gene tests confirmed the nasal type of the lymphoma, with the Epstein-Barr virus present. Staging placed the disease at stage two, local to the nose area. The report frames low-dose treatment as an option worth study.

Catalog record

CREATORSatish Maharaj, Simone Chang
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE7 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11647695

Browse the full library · About the Tower of Babel